Our Strategy
Corporate Information
Our Strategy
       Interview with FinTV
       Update of Relocation Progress of
           Manufacturing Plants of Grand
           Pharm (China)
       Hexun conversations with China
           Grand Pharm CEO
       Acquisition of Wuhan Kernel,
           a long-term strategic development
           to benefit of China Grand Pharm
Announcements and Circulars
Financial Reports
TodayIR Showcase (link)
Useful Links

Hexun conversations with China Grand Pharm CEO

Date: 22/2/2012
Dr. Shao Yan, CEO of the China Grand Pharmaceutical and Healthcare Holdings Limited has attended the “Interview with Executive” event with Hexun, one of the well known financial information provider in China. During the interview, Dr. Shao shared his points of views of the current problems occur in the China pharmaceutical market and future development opportunities, and also discussed about product uniqueness of China Grand Pharm, their advantages and potential, and so on.



Interview Conclusion
Dr. Shao Yan mentioned that through mergers and acquisitions could enhance the competitiveness of China domestic pharmaceutical market. The long-term development of China Grand Pharm will focus on expansion of both pharmaceutical APIs and finished products through the mergers and acquisitions. The product development concept will concentrate in cardiovascular medicines and then ophthalmic products. By adding more resources into R&D projects, China Grand Pharm expect to launch the first Class 1 anti-tumor medicines within the forthcoming five years. The vision of China Grand Pharm would be becoming a well-known Chinese medicine brand in the future, especially in cardiovascular and ophthalmic fields. Strengthen the core competitiveness through technical innovation and industry consolidation. In the international market, China Grand Pharm will participate in the international market with proactive attitude to handle changes in demand, received international standard certifications in APIs segment, to achieve and stand-up a good reputation in the international market.

Sources: Hexun

© 2018 China Grand Pharmaceutical and Healthcare Holdings Limited. All Rights Reserved. Disclaimer Powered by EQS TodayIR